id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15220 R62427 |
Bromley (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 | Motor mean score ≤ 86 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.02 [0.31;3.43] C excluded (control group) |
5/51 7/73 | 12 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15219 R62414 |
Bromley (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 | Motor mean score ≤ 86 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.20 [0.30;4.74] C | 5/51 4/48 | 9 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9946 R35767 |
Videman (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2016 | Griffiths Mental Developmental Scale - Locomotor (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
0.27 [0.04;1.85] excluded (control group) |
-/7 -/8 | - | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9950 R35791 |
Videman (Levetiracetam) (Controls unexposed, disease free), 2016 | Griffiths Mental Developmental Scale - Locomotor (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) | 2.78 [0.66;11.65] | -/7 -/59 | - | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9028 R30773 |
Shallcross (Levetiracetam), 2011 | Locomotor (Griffiths scale) | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) | 0.75 [0.41;1.39] | -/51 -/97 | - | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.08 [0.53;2.22] | 9 | 109 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, disease free; 3: Levetiracetam;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9946, 15220